E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with malignant pleural effusions |
|
E.1.1.1 | Medical condition in easily understood language |
A cancer induced collection of fluid between the lung and the chest wall (malignant pleural effusion). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10026673 |
E.1.2 | Term | Malignant pleural effusion |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. Mean daily breathlessness score over 28 days following randomisation (quantified by visual analogue scale (VAS) scores)
2. Time to pleurodesis failure (proportion requiring further pleural fluid drainage with deaths and loss to follow up censored, log rank test). Pleurodesis failure is defined as: either another ipsilateral pleural drainage procedure to control breathlessness or the patient has symptomatic pleural fluid recurrence but another ipsilateral pleural drainage procedure is not performed due to patient refusal, futility or other medical reason e.g. warfarinisation, poor performance status.
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. A clinically confident diagnosis of pleural malignancy defined as;
a. histocytologically proven pleural malignancy or
b. Otherwise unexplained exudative pleural effusion in the context of clinically proven cancer elsewhere
c. Radiologically proven pleural malignancy as diagnosed in normal clinical practice on thoracic CT in the absence of histocytological proof
2. A significant multi-loculated or multi-septated pleural effusion defined as EITHER:
a) A chest radiograph showing >15% hemithorax area occupied by effusion OR
b) Septated effusion on thoracic ultrasound with a basal parietal to visceral depth of >2cm
3. Malignant pleural effusion requiring drainage and pleurodesis for symptom control.
4. Written informed consent
|
|
E.4 | Principal exclusion criteria |
1. Age < 18 years
2. Expected survival <28 days
3. Previous pneumonectomy on the side of the effusion
4. Positive ipsilateral pleural fluid gram stain or bacterial culture in the previous month.
5. Previously received intra-pleural fibrinolytic agents into this effusion
6. Known sensitivity to urokinase
7. Coincidental stroke, major haemorrhage or major trauma
8. Major surgery in the previous 5 days
9. Chylothorax
10. Known underlying trapped lung of sufficient severity that pleurodesis is futile
11. Patients who are pregnant or lactating
12. Irreversible bleeding diathesis or platelet count <100 x 109
13. Irreversible visual impairment
14. Inability to give informed consent or comply with the protocol
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Mean daily breathlessness score over 28 days following administration (quantified by visual analogue scale (VAS) scores)
2. Time to pleurodesis failure (proportion requiring further pleural fluid drainage with deaths and loss to follow up censored, log rank test). Pleurodesis failure is defined as: either another ipsilateral pleural drainage procedure to control breathlessness
or the patient has symptomatic pleural fluid recurrence but another ipsilateral pleural drainage procedure is not performed due to patient refusal, futility or other medical reason e.g. warfarinisation, poor performance status.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. 28 days
2.1 year/death |
|
E.5.2 | Secondary end point(s) |
1. Radiographic improvement in the area of the pleural effusion (measured as the difference in the proportion of the ipsilateral hemithorax occupied by the pleural effusion opacity on chest radiograph) on day two (the day of pleurodesis).
2. Total volume of pleural fluid drained.
3. Self reported health status (‘quality of life’), quantified from standard questionnaire at each trial assessment: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30).
4. Health care costs (from health care utilisation and cost utility analysis from EQ5D).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. day 2
2. Until drain removal/day 7
3. 28 days, 3, 6, 12 months
4. 1 year |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |